Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of
DCB-AD1 in Patients with Mild to Moderate Alzheimer's Disease. Because of the limitation of
the sample size we could expect but a positive trend of the efficacy unless the effect size
of DCB-AD1 is larger than 0.63. This information will provide us clue if further clinical
investigation such as a phase III study should be carried out in an even larger scale. We
also should be able to obtain valuable experience on the adverse effect of prolonged
(24-week) use of Fo-ti.
Phase:
Phase 2
Details
Lead Sponsor:
National Taiwan University Hospital
Collaborators:
Development Center for Biotechnology, Taiwan Program Office, National Science & Technology, Biotechnology & Pharmaceuticals Taipei Veterans General Hospital, Taiwan